{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T18:43:01Z","timestamp":1767984181512,"version":"3.49.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-025-05671-9","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T03:17:05Z","timestamp":1747624625000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Organizational impact of systematic urine culture before Bacillus Calmette Guerin (BCG) induction instillations"],"prefix":"10.1007","volume":"43","author":[{"given":"Quentin","family":"Jock","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura I.","family":"Levi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthieu","family":"Lafaurie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annabelle","family":"Goujon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Mongiat Artus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Meria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francois","family":"Desgrandchamps","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Masson Lecomte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilien","family":"Seizilles de Mazancourt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,19]]},"reference":[{"key":"5671_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1046\/j.1464-410x.2001.02306.x","volume":"88","author":"MD Shelley","year":"2001","unstructured":"Shelley MD, Kynaston H, Court J et al (2001) A systematic review of intravesical bacillus Calmette-Gu\u00e9rin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int 88:209\u2013216. https:\/\/doi.org\/10.1046\/j.1464-410x.2001.02306.x","journal-title":"BJU Int"},{"key":"5671_CR2","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","volume":"56","author":"P-U Malmstr\u00f6m","year":"2009","unstructured":"Malmstr\u00f6m P-U, Sylvester RJ, Crawford DE et al (2009) An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Gu\u00e9rin for non-muscle-invasive bladder cancer. Eur Urol 56:247\u2013256. https:\/\/doi.org\/10.1016\/j.eururo.2009.04.038","journal-title":"Eur Urol"},{"key":"5671_CR3","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","volume":"81","author":"M Babjuk","year":"2022","unstructured":"Babjuk M, Burger M, Capoun O et al (2022) European association of urology guidelines on Non\u2013muscle-invasive bladder Cancer (Ta, T1, and carcinoma in Situ). Eur Urol 81:75\u201394. https:\/\/doi.org\/10.1016\/j.eururo.2021.08.010","journal-title":"Eur Urol"},{"key":"5671_CR4","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.purol.2022.08.006","volume":"32","author":"Y Neuzillet","year":"2022","unstructured":"Neuzillet Y, Prad\u00e8re B, Xylinas E et al (2022) French AFU Cancer committee Guidelines - Update 2022\u20132024: Non-muscle-invasive bladder cancer (NMIBC). Prog En Urol 32:1102\u20131140. https:\/\/doi.org\/10.1016\/j.purol.2022.08.006","journal-title":"Prog En Urol"},{"key":"5671_CR5","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.annfar.2012.06.009","volume":"31","author":"S Molliex","year":"2012","unstructured":"Molliex S, Pierre S, Bl\u00e9ry C et al (2012) Examens pr\u00e9interventionnels syst\u00e9matiques. Ann Fr Anesth R\u00e9animation 31:752\u2013763. https:\/\/doi.org\/10.1016\/j.annfar.2012.06.009","journal-title":"Ann Fr Anesth R\u00e9animation"},{"key":"5671_CR6","doi-asserted-by":"publisher","unstructured":"Saint F (2021) Gestion pratique de l\u2019ECBU au cours des instillations endov\u00e9sicales de Bacille de Calmette et Gu\u00e9rin (BCG) et de Mitomycine C (MMC). Prog En Urol - FMC 31:F121\u2013F126. https:\/\/doi.org\/10.1016\/j.fpurol.2021.09.003","DOI":"10.1016\/j.fpurol.2021.09.003"},{"key":"5671_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000477673","volume":"99","author":"S Poletajew","year":"2017","unstructured":"Poletajew S, Zapa\u0142a P, Radziszewski P (2017) Safety and efficacy of intravesical Bacillus Calmette-Gu\u00e9rin immunotherapy in patients with Non-Muscle-Invasive bladder Cancer presenting with asymptomatic bacteriuria: A systematic review. Urol Int 99:1\u20135. https:\/\/doi.org\/10.1159\/000477673","journal-title":"Urol Int"},{"key":"5671_CR8","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.eururo.2012.08.013","volume":"63","author":"HW Herr","year":"2013","unstructured":"Herr HW (2013) Intravesical Bacille Calmette-Gu\u00e9rin eradicates bacteriuria in Antibiotic-na\u00efve bladder Cancer patients. Eur Urol 63:832\u2013835. https:\/\/doi.org\/10.1016\/j.eururo.2012.08.013","journal-title":"Eur Urol"},{"key":"5671_CR9","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1159\/000521288","volume":"91","author":"ME Charlson","year":"2022","unstructured":"Charlson ME, Carrozzino D, Guidi J, Patierno C (2022) Charlson comorbidity index: A critical review of clinimetric properties. Psychother Psychosom 91:8\u201335. https:\/\/doi.org\/10.1159\/000521288","journal-title":"Psychother Psychosom"},{"key":"5671_CR10","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.eururo.2020.12.033","volume":"79","author":"RJ Sylvester","year":"2021","unstructured":"Sylvester RJ, Rodr\u00edguez O, Hern\u00e1ndez V et al (2021) European association of urology (EAU) prognostic factor risk groups for Non\u2013muscle-invasive bladder Cancer (NMIBC) incorporating the WHO 2004\/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC guidelines panel. Eur Urol 79:480\u2013488. https:\/\/doi.org\/10.1016\/j.eururo.2020.12.033","journal-title":"Eur Urol"},{"key":"5671_CR11","doi-asserted-by":"publisher","first-page":"E658","DOI":"10.1111\/j.1464-410X.2012.11405.x","volume":"110","author":"HW Herr","year":"2012","unstructured":"Herr HW (2012) Outpatient urological procedures in antibiotic-naive patients with bladder cancer with asymptomatic bacteriuria: Urological procedures in patients with asymptomatic bacteriuria. BJU Int 110:E658\u2013E660. https:\/\/doi.org\/10.1111\/j.1464-410X.2012.11405.x","journal-title":"BJU Int"},{"key":"5671_CR12","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.juro.2011.10.032","volume":"187","author":"HW Herr","year":"2012","unstructured":"Herr HW (2012) Intravesical Bacillus Calmette-Gu\u00e9rin outcomes in patients with bladder Cancer and asymptomatic bacteriuria. J Urol 187:435\u2013437. https:\/\/doi.org\/10.1016\/j.juro.2011.10.032","journal-title":"J Urol"},{"key":"5671_CR13","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/nrurol.2013.149","volume":"10","author":"JA Rodriguez-Nieves","year":"2013","unstructured":"Rodriguez-Nieves JA, Macoska JA (2013) Prostatic fibrosis, lower urinary tract symptoms, and BPH. Nat Rev Urol 10:546\u2013550. https:\/\/doi.org\/10.1038\/nrurol.2013.149","journal-title":"Nat Rev Urol"},{"key":"5671_CR14","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1001\/archinte.166.21.2381","volume":"166","author":"V Kupelian","year":"2006","unstructured":"Kupelian V, Wei JT, O\u2019Leary MP et al (2006) Prevalence of lower urinary tract symptoms and effect on quality of life in a Racially and ethnically diverse random sample: the Boston area community health (BACH) survey. Arch Intern Med 166:2381\u20132387. https:\/\/doi.org\/10.1001\/archinte.166.21.2381","journal-title":"Arch Intern Med"},{"key":"5671_CR15","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.eururo.2013.07.021","volume":"65","author":"M Brausi","year":"2014","unstructured":"Brausi M, Oddens J, Sylvester R et al (2014) Side effects of Bacillus Calmette-Gu\u00e9rin (BCG) in the treatment of Intermediate- and High-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC Genito-Urinary cancers group randomised phase 3 study comparing One-third dose with full dose and 1 year with 3 years of maintenance BCG. Eur Urol 65:69\u201376. https:\/\/doi.org\/10.1016\/j.eururo.2013.07.021","journal-title":"Eur Urol"},{"key":"5671_CR16","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/S0302-2838(03)00371-3","volume":"44","author":"RJ Sylvester","year":"2003","unstructured":"Sylvester RJ, Van Der Meijden APM, Oosterlinck W et al (2003) The side effects of Bacillus Calmette-Guerin in the treatment of Ta T1 bladder Cancer do not predict its efficacy: results from a European organisation for research and treatment of Cancer Genito-Urinary group phase III trial. Eur Urol 44:423\u2013428. https:\/\/doi.org\/10.1016\/S0302-2838(03)00371-3","journal-title":"Eur Urol"},{"key":"5671_CR17","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.juro.2006.04.104","volume":"176","author":"M Colombel","year":"2006","unstructured":"Colombel M, Saint F, Chopin D et al (2006) The effect of Ofloxacin on Bacillus Calmette-Guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, Double-Blind, placebo controlled, multicenter study. J Urol 176:935\u2013939. https:\/\/doi.org\/10.1016\/j.juro.2006.04.104","journal-title":"J Urol"},{"key":"5671_CR18","doi-asserted-by":"publisher","unstructured":"Durek C, R\u00fcsch-Gerdes S, Jocham D, B\u00f6hle A (2000) Sensitivity of BCG to modern antibiotics. Eur Urol 37 Suppl 121\u201325. https:\/\/doi.org\/10.1159\/000052378","DOI":"10.1159\/000052378"},{"key":"5671_CR19","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1111\/j.1464-410X.2011.10528.x","volume":"109","author":"IM Cullen","year":"2012","unstructured":"Cullen IM, Manecksha RP, McCullagh E et al (2012) The changing pattern of antimicrobial resistance within 42,033 Escherichia coli isolates from nosocomial, community and urology patient-specific urinary tract infections, Dublin, 1999\u20132009. BJU Int 109:1198\u20131206. https:\/\/doi.org\/10.1111\/j.1464-410X.2011.10528.x","journal-title":"BJU Int"},{"key":"5671_CR20","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1016\/j.euf.2021.06.007","volume":"8","author":"S Ourfali","year":"2022","unstructured":"Ourfali S, Matillon X, Ricci E et al (2022) Prognostic implications of treatment delays for patients with Non-muscle-invasive bladder Cancer. Eur Urol Focus 8:1226\u20131237. https:\/\/doi.org\/10.1016\/j.euf.2021.06.007","journal-title":"Eur Urol Focus"},{"key":"5671_CR21","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.eururo.2020.04.066","volume":"78","author":"M-O Grimm","year":"2020","unstructured":"Grimm M-O, Van Der Heijden AG, Colombel M et al (2020) Treatment of High-grade Non\u2013muscle-invasive bladder carcinoma by standard number and dose of BCG instillations versus reduced number and standard dose of BCG instillations: results of the European association of urology research foundation randomised phase III clinical trial NIMBUS. Eur Urol 78:690\u2013698. https:\/\/doi.org\/10.1016\/j.eururo.2020.04.066","journal-title":"Eur Urol"},{"key":"5671_CR22","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1159\/000471561","volume":"16","author":"A Steg","year":"1989","unstructured":"Steg A, Leleu C, Debr\u00e9 B et al (1989) Systemic Bacillus Calmette-Gu\u00e9rin infection, \u2018bcgitis\u2019, in patientstreated by intravesical Bacillus Calmette-Gu\u00e9rin therapy forbladder Cancer. Eur Urol 16:161\u2013164. https:\/\/doi.org\/10.1159\/000471561","journal-title":"Eur Urol"},{"key":"5671_CR23","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1111\/bju.14793","volume":"124","author":"ES Larsen","year":"2019","unstructured":"Larsen ES, Nordholm AC, Lillebaek T et al (2019) The epidemiology of Bacille Calmette\u2013Gu\u00e9rin infections after bladder instillation from 2002 through 2017: a nationwide retrospective cohort study. BJU Int 124:910\u2013916. https:\/\/doi.org\/10.1111\/bju.14793","journal-title":"BJU Int"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05671-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-025-05671-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05671-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T13:54:59Z","timestamp":1767966899000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-025-05671-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,19]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5671"],"URL":"https:\/\/doi.org\/10.1007\/s00345-025-05671-9","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,19]]},"assertion":[{"value":"22 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was retrospective and was approved by the Commission National Informatique et Libert\u00e9s (CNIL) and the Comit\u00e9 d\u2019Ethique et Recherche en Urology (CERU) which are the French data protection agency and ethics committee, respectively. Patients were informed of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"316"}}